A prospective study of cannabis use as a risk factor for non-adherence and treatment dropout in first-episode schizophrenia

Schizophrenia Research

Volumn 113, Issue 2-3, 2009, Pages 138-144

  Miller, Rachel ^a   Ream, Geoffrey ^b   McCormack, Joanne ^a   Gunduz Bruce, Handan ^a   Sevy, Serge ^a   Robinson, Delbert ^a  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b ADELPHI UNIVERSITY   (United States)

Author keywords

Adherence; Cannabis; Compliance; Dropout; First episode; Schizophrenia; Substance abuse

Indexed keywords

OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; CANNABIS ADDICTION; COMORBIDITY; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SCHIZOPHRENIA; TREATMENT REFUSAL;

ADOLESCENT; ADULT; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MARIJUANA ABUSE; PATIENT COMPLIANCE; PATIENT DROPOUTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; YOUNG ADULT;

EID: 68049139264     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2009.04.018     Document Type: Article

References (36)

1. Addington J., and Addington D. Impact of an early psychosis program on substance use. Psychiatr. Rehabil. J. 25 1 (2001) 60-67
2. Birchwood M., Todd P., and Jackson C. Early intervention in psychosis. The critical period hypothesis. Br. J. Psychiatry 172 33 (1998) 53-59
3. Bottlender R., Sato T., Jager M., Groll C., Strauss A., and Moller H.J. The impact of duration of untreated psychosis and premorbid functioning on outcome of first inpatient treatment in schizophrenia and schizoaffective patients. Eur. Arch. Psychiatry Clin. Neurosci. 252 (2002) 226-231
4. Buhler B., Hambrecht M., Loffler W., Heiden W., and Hafner H. Precipitation and determination of the onset and course of schizophrenia by substance abuse-a retrospective and prospective study of 232 population-based first illness episodes. Schizophr. Res. 54 (2002) 243-251
5. Coldham E.L., Addington J., and Addington D. Medication adherence of individuals with a first episode of psychosis. Acta. Psychiatr. Scand. 106 (2002) 286-290
6. Drake R.E., Osher F.C., Noordsy D.L., Teague G.B., Hurlbut S.C., and Beaudett M.S. Diagnosis of alcohol use disorders in schizophrenia. Schizophr. Bull. 16 (1990) 57-67
7. First M.B., Spitzer R.L., Gibbon M., and Williams J.B. Structured Clinical Interview for DSM-IV Axis I Disorders - Patient Edition (SCID-I/P, Version 2.0, 8/98 revision) (1998), Biometrics Research Department, New York
8. Gaebel W., Janner M., Frommana N., Pietzcker A., Kopcke W., Linden M., et al. First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies. Schizophr. Res. 53 (2002) 145-159
9. Garavan J., Browne S., Gervin M., Lane A., Larkin C., and O 'Callaghan E. Compliance with neuroleptic medication in outpatients with schizophrenia: relationship to subjective response to neuroleptics; attitudes to medication and insight. Compr. Psychiatry 39 4 (1998) 215-219
10. Green A.I., Tohen M.F., Hamer R.M., Strakowski S.M., Lieberman J.A., Glick, et al. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophr. Res. 66 (2004) 125-135
11. Hambrecht M., and Hafner H. Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective. Aust. N. Z. J. Psychiatry 34 3 (2000) 468-475
12. Hollingshead A.B., and Reidlich F.C. Social Class and Mental Illness: A Community Study (1958), Wiley, New York
13. Kamali M., Kelly B.D., Clark M., Browne S., Gervin M., Kinsella A., et al. A prospective evaluation of adherence to medication in first episode schizophrenia. Eur. Psychiatr. 21 (2006) 29-33
14. Lacro J.P., Dunn L.B., Dolder C.R., Leckband S.G., and Jeste D.V. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J. Clin. Psychiatry 63 (2002) 892-909
15. Larsen T.K., Johannessen J.O., and Opjordsmoen S. First-episode schizophrenia with long duration of untreated psychosis. Pathways to care. Br. J. Psychiatry 172 (1998) 45-52
16. Larsen T.K., Melle I., Auestad B., Friis S., Haahr U., Johannessen J.O., et al. Substance abuse in first-episode non-affective psychosis. Schizophr. Res. 88 (2006) 55-62
17. Linden M., Godemann F., Gaebel W., Kopke W., Muller P., Muller-Spahn F., et al. A prospective study of factors influencing adherence to a continuous neuroleptic treatment program in schizophrenia patients during 2 years. Schizophr. Bull. 27 4 (2001) 585-596
18. Linszen D.H., Dingermans P.M., and Lenior M.E. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch. Gen. Psychiatry 51 (1994) 273-279
19. Linszen D.H., Dingermans P.M., and Lenior M.E. Early intervention and a five year follow up in young adults with a short duration of untreated psychosis: ethical implications. Schizophr. Res. 51 (2001) 55-61
20. Miller R., McCormack Caponi J., Sevy S., and Robinson D. The insight-adherence-abstinence triad: an integrated treatment focus for cannabis-using first-episode schizophrenia patients. Bull. Menninger. Clin. 69 (2005) 220-236
21. Mojtabai R., Lavelle J., Gibson P.J., Sohler N.L., Craig T.J., Carlson G.A., et al. Gaps in use of antipsychotics after discharge by first-admission patients with schizophrenia, 1989 to 1996. Psychiatr. Serv. 53 3 (2002) 337-339
22. Mutsatsa S.H., Joyce E.M., Hutton S.B., Webb E., Gibbins H., Paul S., et al. Clinical correlates of early medication adherence: west London first episode schizophrenia study. Acta. Psychiatr. Scand. 108 (2003) 439-446
23. Novak-Grubic V., and Tavcar R. Predictors of noncompliance in males with first-episode schizophrenia, schizophreniform and schizoaffective disorder. Eur. Psychiatr. 17 3 (2002) 148-154
24. Opolka J.L., Rascati K.L., Brown C.M., and Gibson P.J. Role of ethnicity in predicting antipsychotic medication adherence. Ann. Pharmacother. 37 (2003) 625-630
25. Penetar D.M., Kouri E.M., Gross M.M., McCarthy E.M., Rhee C.K., Peters E.N., et al. Transdermal nicotine alters some of marihuana's effects in male and female volunteers. Drug Alcohol Depend. 79 2 (2005) 211-223
26. Perkins D.O., Johnson J.L., Hamer R.M., Zipursky R.B., Keefe R.S., Centorrhino F., et al. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic edpisode. Schizophr. Res. 83 (2006) 53-63
27. Ream G.L., Benoit E., Johnson B.D., and Dunlap E. Smoking tobacco along with marijuana increases symptoms of cannabis dependence. Drug Alcohol Depend. 95 (2008) 199-208
28. Robinson D.G., Woerner M.G., Alvir J.M., Geisler S., Koreen A., Sheitmen B., et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am. J. Psychiatry 156 (1999) 544-549
29. Robinson D.G., Woerner M.G., Alvir J.M., Bilder R.M., Hinrichsen G.A., and Lieberman J.A. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr. Res. 57 (2002) 209-219
30. Robinson D.G., Woerner M.G., Napolitano B., Patel R.C., Sevy S.M., Gunduz-Bruce H., et al. Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. Am. J. Psychiatry 163 (2006) 2096-2102
31. Spitzer R.L., and Endicott J. Schedule for Affective Disorders and Schizophrenia-Change Version. 3rd ed. (1978), New York State Psychiatric Institute
32. Svedberg B., Mesterton A., and Cullberg. First-episode non-affective psychosis in a total urban population: a 5-year follow-up. Soc. Psychiatry Psychiatr. Epidemiol. 36 7 (2001) 322-337
33. Van Mastrigt S., Addington J., and Addington D. Substance misuse at presentation to an early psychosis program. Soc. Psychiatry Psychiatr. Epidemiol. 39 (2004) 69-72
34. Verdoux H., Lengronne J., Liraud F., Gonzales B., Assens F., Abalan F., et al. Medication adherence in psychosis: predictors and impact on outcome. A 2-year follow-up of first-admitted subjects. Acta. Psychiatr. Scand. 102 (2000) 203-210
35. Wade D., Harrigan S., Edwards J., Burgess P.M., Whelan G., and McGorry P.D. Course of substance misuse and daily tobacco use in first-episode psychosis. Schizophr. Res. 81 (2006) 145-150
36. Wamala S., Merlo J., Bostrom G., Hogstedt C., and Agren G. Socioeconomic disadvantage and primary non-adherence with medication in Sweden. Int. J. Qual. Health Care 19 (2007) 134-140